Jinyu Bio-Technology Co Net Tangible Assets
The Net Tangible Assets of Jinyu Bio-Technology Co (600201.SS) as of Oct 13, 2026 is 5.36 B CNY. In the previous year, Net Tangible Assets was 4.65 B CNY — a change of 15.18% (higher).
Get this data via API
Financial Data API
Net Tangible Assets
5.36 BCNY
YoY
15.18%
Last updated:
The Jinyu Bio-Technology Co Net Tangible Assets history
3 Years
10 Years
25 Years
Max
| YEAR | Net Tangible Assets | YoY |
|---|---|---|
| 5.36 BCNY | +15.18% | |
| 4.65 BCNY | +0.58% | |
| 4.63 BCNY | +5.77% | |
| 4.37 BCNY | -3.42% | |
| 4.53 BCNY | +6.05% | |
| 4.27 BCNY | +6.85% | |
| 4.00 BCNY | -9.27% | |
| 4.40 BCNY | +7.00% | |
| 4.12 BCNY | +18.30% | |
| 3.48 BCNY | +76.54% | |
| 1.97 BCNY | +25.50% | |
| 1.57 BCNY | — |
Jinyu Bio-Technology Co Stock analysis
Frequently Asked Questions about Jinyu Bio-Technology Co stock
Net Tangible Assets of Jinyu Bio-Technology Co is 5.36 B CNY in 2025.
Net Tangible Assets of Jinyu Bio-Technology Co changed from 4.65 B CNY to 5.36 B CNY, representing a 15.18% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Net Tangible Assets Jinyu Bio-Technology Co since 2006 – with annual values, charts, and detailed analysis.
Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.
Net Tangible Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Jinyu Bio-Technology Co historically and in real time.
Balance Sheet — Jinyu Bio-Technology Co
All Key Metrics — Jinyu Bio-Technology Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth